Have Indian Scientists Discovered A Veterinary Drug That Suppresses Cancer?

Fenbendazole, a wide-ranging anti-parasitic medication used in the veterinarian industry, has been discovered to be effective against cancer by Indian researchers.

Table of Contents

Does Fenbendazole Really Suppress & Cure Cancer?

Fenbendazole has a huge potential for production as an important anti-cancer drug, according to researchers at Panjab University. It’s now being used to cure parasitic worm diseases in horses and other species. The findings of the research were presented in the scientific journal Scientific Reports.

Researchers used the immunofluorescence method to examine the efficacy of fenbendazole after treating human ‘non-small cell lung cancer cells’ (a kind of lung cancer cell) with the drug. The medication induces a partial modification of the microtubule network around the cell nucleus, according to the researchers. In the presence of wild type p53 tumor suppressor gene, tumour cell lines also showed increased cell demise activity.

Mice Fed Fenbendazole In Test & Cancerous Tumors Died

Researchers fed fenbendazole to mice every other day for 12 days to see how effective it was. Tumors were excised, counted, and weighed at the conclusion of the 12th day.

The scale and weight of the tumors is considered to be reduced by the researchers. Fenbendazole seems to suppress tumor cell development in vivo by causing tumor cell apoptosis, according to the findings.

Cancer cells have been seen to have enhanced glucose uptake in order to meet their energy needs. As a result, researchers looked into how fenbendazole affected glucose absorption in human cancer cells. Fenbendazole was used to treat two related kinds of cancer cells, H460 and A549 cells.

Glucose absorption was inhibited in both cell lines, according to the researchers

Fenbendazole, according to experts, can also be useful in avoiding medication resistance, which is typical in cancer treatment. Since the beginning of the tumorigenesis phase, a variety of genes and proteins that modify different cell signaling pathways are involved in the reduction of tumor size in mice fed fenbendazole for 12 days. Drugs with a single goal have a low effectiveness rate, which may contribute to drug tolerance. Drugs with several cellular goals, on the other hand, are predicted to have increased effectiveness as well as the potential to avoid the development of tolerance.

Our findings indicate that fenbendazole works through mild microtubule destruction, p53 stabilization, and glucose metabolism intervention, contributing to preferential removal of cancer cells both in vitro and in vivo

said Dr. Tapas Mukhopadhyay, former director of NCHGSR, who led the research, in an interview with India Science Wire.

Microtubule targeting agents (MTAs) are often used to treat a variety of tumor forms, but their efficacy is often hampered by drug resistance.

New drug production typically takes a significant amount of time, resources, and commitment. It will take many years to transform a successful molecule into a marketable medication. As a result, it is important to employ tactics to solve these roadblocks. Repurposing veterinary medicines that have shown promise for human usage will reduce the amount of time and money it takes to produce new drugs Dr. Mukhopadhyay expressed his thoughts on the topic.

Fenbendazole has a high protection margin, according to the researchers, and it is well accepted among most animals. In laboratory animals, it has a relatively low level of toxicity and a very high level of reliability. As a result, it could be a promising candidate for anticancer treatment.

Fenbendazole may also be used as a supplement to other treatments.

“The FDA, as well as other reported pre-clinical evidence on toxicological trials conducted on animals, indicates that fenbendazole administered at dosages many times the permitted dose has no harmful effects in animals. Furthermore, fenbendazole was shown to have limited toxicity in regular human cells in a previous review. FZ may be an excellent candidate for production as an anti-cancer agent based on this knowledge “Dr. Mukhopadhyay went on to say,

The study team also included Dr. Nilambra Dogra from the Postgraduate Institute of Medical Education and Research, Chandigarh, in addition to Dr. Mukhopadhyay and Dr. Ashok Kumar from Panjab University.

Leave a comment